AXSM

AXS-07

Migraine

Stage (next event)

Expected Date

NDA Filing

Q1 2021

Catalyst Info & Data Links

TITLE: AXS-07 for Migraine NDA Filing

  • Clinical Trial (link) Name of trial


WHAT IS THE NEXT CATALYST EVENT?

  • NDA Filing 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q1 2021


PRIOR DATA/EVENTS

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION 

  • The components of AXS-07, MoSEIC™ meloxicam and rizatriptan, are combined for a potentially synergistic effect with enhanced efficacy over currently available therapies in the treatment of migraine. Meloxicam is an NSAID that provides potent pain relief with a long duration of action. However, standard meloxicam has an extended time to maximum plasma concentration (Tmax). AXS-07 utilizes Axsome’s proprietary MoSEIC™ technology to achieve rapid peak plasma levels of meloxicam after oral administration without compromising its long half-life.  Rizatriptan is currently approved as a single agent for the acute treatment of migraine and targets different migraine-inducing CNS receptor systems than meloxicam

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon